Compare AbbVie Inc (ABBV) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Procter & Gamble Co — how do they compare? AbbVie Inc trades at $249.52 (market cap $438.19B), while Procter & Gamble Co trades at $145.12 (market cap $340.39B). The key difference: AbbVie Inc is the larger of the two by market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| ABBV | PG | |
|---|---|---|
Market Cap | $438.19B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $167.18 |
52-Week Low | $197.38 | $138.10 |
Enterprise Value | $502.45B | $366.23B |
Dividend Yield | 2.79% | 2.97% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 1.59% with bullish technical signals and strong analyst support. The company demonstrates solid revenue growth to $61.16B in 2025, though net margins have compressed to 6.9%. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.65 surpassing estimates. Technical indicators show bullish momentum with the current price near resistance at $249, while RSI suggests potential oversold conditions at lower timeframes.
AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 price target offering 12.6% upside. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s and regulatory risks require monitoring. The company's dividend growth streak and robust pipeline support long-term value, but investors should weigh execution risks against current valuation multiples.
Procter & Gamble (PG) trades at $145.21, down 0.39% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding expectations, and a robust 18.44% net income margin. Recent news highlights its dividend reliability and supply chain improvements, while analyst consensus is bullish with a $161.20 price target.
Outlook remains positive due to steady profitability and dividend growth, but risks include premium valuation and economic sensitivity. Investors may find value in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
